Thursday, March 6, 2014

Live demonstrations of 3D printing technology.

SYS Systems is set to wow the crowds at MACH 2014 with live demonstrations of 3D printing technology.
Skilled technicians will be on-site to show visitors how the process works using cutting edge Fortus and Objet additive manufacturing technologies from Stratasys.
Seen as the gateway to in-house digital additive manufacturing, the Stratasys Fortus 250 builds parts so durable and accurate that most customers find its use expands way beyond functional testing and into tooling, jigs, fixtures and more besides.
Designed purposely as an affordable production series machine, the Fortus 250 combines compact size and ease of use with sophisticated Insight software. And best of all, its ABSplusparts are accurate, stable, durable and repeatable. Three layer resolutions are available to let customers print in fine detail or at maximum speed. A free support removal system will be offered with any Fortus or Connex order placed at the exhibition.
The other machine in the spotlight on SYS Systems’ 18 sq m stand will be the Stratasys Objet 30 Pro 3D printer. This is the only desktop 3D printer in the world that can print in up to seven different materials, including transparent and high temperature photopolymers. A large tray size gets the most out of a small footprint, allowing users to create stunningly realistic models right in the office.
At MACH, the Objet 30 Pro will be performing live demonstrations of printing a closed case part – a component that highlights the fine production capabilities of this innovative desktop range.
Both machines are intended to underline the company’s main theme at MACH, which is to bring 3D printing in-house to save time and money in prototyping. The SYS Systems team will be on hand throughout the exhibition to show how much it costs to print in-house versus the use of bureau services. The company’s sales team will be happy to evaluate customer products and provide estimated cost and time savings which can be supported by future trials if requested.

No comments:

Post a Comment